Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
Olian Judy D. reported acquisition or exercise transactions in this Form 4 filing.
United Therapeutics Corporation director Judy D. Olian received an annual non-employee director equity award of 760 restricted stock units (RSUs) on July 22, 2026. Each RSU entitles her to one share of common stock after vesting, with full vesting on the earlier of the one-year anniversary of grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this award, she holds 760 RSUs and 5,555 shares of common stock directly. The RSUs have no expiration date.
United Therapeutics director Jan Malcolm received equity compensation grants. On July 22, 2026, Malcolm was granted 380 restricted stock units and stock options for 1,190 shares of common stock at an exercise price of $527.07, as annual non-employee director awards. These awards vest on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following the grants, Malcolm directly holds 380 RSUs, 3,570 stock options and 450 common shares. The awards were reported as made pursuant to a Rule 10b5-1 trading arrangement.
United Therapeutics Corporation director Nilda Mesa received annual non-employee director equity awards on July 22, 2026, consisting of 380 restricted stock units and 1,190 stock options. Each restricted stock unit represents the right to receive one common share upon vesting. The options carry a $527.0700 exercise price and, together with the RSUs, are scheduled to become fully vested on the earlier of the one-year anniversary of the grant date or the next Annual Meeting of Shareholders, anticipated for June 25, 2027. After these awards, Mesa directly holds 5,678 shares of United Therapeutics common stock.
United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027, and expire on July 22, 2033. After this filing, he holds 2,983 common shares directly and 1,457 shares indirectly through a trust over which he has sole investment and voting power; totals were updated to correct a prior underreporting of 590 trust shares.
United Therapeutics Corp director Christopher Causey received an annual non-employee director stock option award covering 2,380 shares of common stock at a $527.07 exercise price, expiring July 22, 2033. The options become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, he directly holds 4,190 common shares and options on 2,380 shares.
United Therapeutics director Christopher Patusky received a grant of 2,380 stock options on July 22, 2026, with an exercise price of $527.07 per share, expiring July 22, 2033. This annual non-employee director award becomes fully vested on the earlier of the one-year anniversary of the grant date or the date of the next Annual Meeting of Shareholders, which is anticipated to be June 25, 2027. Following the grant, he directly holds 2,380 options under this award and 2,410 shares of common stock.
Giltner Richard reported acquisition or exercise transactions in this Form 4 filing.
United Therapeutics Corp director Richard Giltner received an annual non-employee director award of 760 restricted stock units, each representing one share of common stock upon vesting.
The RSUs vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. After this award he holds 760 RSUs and 21,884 common shares directly.
United Therapeutics Corp director Ray Kurzweil received annual equity awards consisting of 380 restricted stock units and 1,190 stock options on July 22, 2026. The awards vest in full on the earlier of the one-year anniversary of the grant or the next Annual Meeting, anticipated on June 25, 2027. The options carry an exercise price of $527.07 per share and expire on July 22, 2033. Following these awards, he directly holds 13,320 shares of United Therapeutics common stock. The restricted stock units have no expiration date and each converts into one share upon vesting.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 22, 2026 and sold 9,500 shares in multiple trades at weighted-average prices reported from $524.27 to $539.47 per share. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following the exercise, family trusts held 293,910 stock options, while Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly through a spouse.
United Therapeutics Corporation appointed Victor Dzau, M.D. to its Board of Directors on July 22, 2026 and increased the Board size to 13 members, following a recommendation from the Nominating and Governance Committee.
Upon joining, Dr. Dzau received equity awards under the 2026 Stock Incentive Plan, consisting of an initial grant of 380 restricted stock units and 1,190 stock options, plus pro-rata grants of 350 restricted stock units and 1,110 stock options for the remainder of the 2026-2027 Board service year. He will initially serve without committee assignments, be compensated under the standard non-employee director program, and be covered by the company’s standard director indemnification agreement.
The company states that there are no transactions over $120,000 involving Dr. Dzau that would constitute related-party dealings and describes his addition as part of an ongoing Board refreshment effort aligned with its public benefit mission in rare diseases and transplantable organ technologies.